Your browser doesn't support javascript.
loading
Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.
Orsi, Douglas L; Ferrara, Steven J; Siegel, Stephan; Friberg, Anders; Bouché, Léa; Pook, Elisabeth; Lienau, Philip; Bluck, Joseph P; Lemke, Christopher T; Akcay, Gizem; Stellfeld, Timo; Meyer, Hanna; Pütter, Vera; Holton, Simon J; Korr, Daniel; Jerchel-Furau, Isabel; Pantelidou, Constantia; Strathdee, Craig A; Meyerson, Matthew; Eis, Knut; Goldstein, Jonathan T.
Afiliação
  • Orsi DL; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Ferrara SJ; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Siegel S; Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Friberg A; Nuvisan ICB GmbH, 13353 Berlin, Germany.
  • Bouché L; Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Pook E; Research and Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany.
  • Lienau P; Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Bluck JP; Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Lemke CT; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Akcay G; Bayer US LLC, Research and Development Precision Molecular Oncology, Cambridge, MA 02142, USA.
  • Stellfeld T; Nuvisan ICB GmbH, 13353 Berlin, Germany.
  • Meyer H; Nuvisan ICB GmbH, 13353 Berlin, Germany.
  • Pütter V; Nuvisan ICB GmbH, 13353 Berlin, Germany.
  • Holton SJ; Nuvisan ICB GmbH, 13353 Berlin, Germany.
  • Korr D; Nuvisan ICB GmbH, 13353 Berlin, Germany.
  • Jerchel-Furau I; Bayer US LLC, Research and Development Precision Molecular Oncology, Cambridge, MA 02142, USA.
  • Pantelidou C; Bayer US LLC, Research and Development Precision Molecular Oncology, Cambridge, MA 02142, USA.
  • Strathdee CA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Meyerson M; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics and Medicine, Harvard Medical Sch
  • Eis K; Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • Goldstein JT; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: jgold@broadinstitute.org.
Bioorg Med Chem ; 78: 117130, 2023 01 15.
Article em En | MEDLINE | ID: mdl-36542958
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / PPAR gama Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / PPAR gama Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article